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Purpose: The present study was aimed to assess the feasibility of using decellular-
ized aortic allograft in a rat small animal surgical model for conducting small diam-
eter vascular tissue engineering research. Materials and Methods: Decellularized 
aortic allografts were infra-renally implanted in 12 Sprague-Dawley (SD) adult rats. 
The conduits were harvested at 2 (n = 6) and 8 weeks (n = 6), and assessed by he-
matoxylin and eosin (H&E), van Gieson, Masson Trichrome staining, and immu-
nohistochemistry for von Willebrand factor, CD 31+, and actin. Results: Consistent, 
predictable, and reproducible results were produced by means of a standardized sur-
gical procedure. All animals survived without major complications. Inflammatory 
immune reaction was minimal, and there was no evidence of aneurysmal degenera-
tion or rupture of the decellularized vascular implants. However, the aortic wall ap-
peared thinner and the elastic fibers in the medial layer showed decreased undula-
tion compared to the normal aorta. There was also minimal cellular repopulation of 
the vascular media. The remodeling appeared progressive from 2 to 8 weeks with 
increased intimal thickening and accumulation of both collagen and cells staining 
for actin. Although the endothelial like cells appeared largely confluent at 8 weeks, 
they were not as concentrated in appearance as in the normal aorta. Conclusion: 
The results showed the present rat animal model using decellularized vascular al-
lograft implants to be a potentially durable and effective experimental platform for 
conducting further research on small diameter vascular tissue engineering.
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INTRODUCTION
There is a growing need for a clinically applicable and biologically compatible 
small-diameter vascular conduit. Currently, the autologous reversed saphenous vein 
graft (SVG) is the most widely used and time proven conduit, not only for coronary Seong-Jun Hwang, et al.
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ration. IVC heparin (10 IU/100 g body weight) injection 
was performed after which the aorta was clamped just dis-
tally to the renal artery and proximally to the iliac bifurca-
tion. The mid portion of the isolated aorta was transected. 
The four opposing edges of the decellularized graft (two 
proximal and two distal) were sutured to the corresponding 
edges of the native vessel with #8-0 polypropylene sutures. 
Mosquito clamps were applied to each suture arm for trac-
tion. The anterior margins of the proximal and distal native 
aorta were anastomosed with the graft using multiple inter-
rupted Nylon #9-0 sutures. The aorta was then rotated 180 
degrees by reversing the traction sutures from left to right 
which resulted in exposure of the unsutured posterior mar-
gins. Anastomosis was performed in an identical manner 
with Nylon #9-0 sutures (Fig. 1). No additional anticoagu-
lation was performed postoperatively. Ketoprofen 5 mg/kg 
sc daily and Amoxicillin 150 mg/kg sc x twice daily were 
administered for 3 days postoperatively for pain and pro-
phylaxis against infection. All surgeries were performed in 
an environment that was largely specific pathogen-free 
(SPF). Animals were managed according to the “Revised 
Guide for the Care and Use of Laboratory Animals” pre-
pared by the Institute of Laboratory Animal Resources and 
published by the National Institutes of Health, revised and 
published in 1996.8
Tissue decellularization
The rat infrarenal abdominal aorta was harvested for decellu-
larization as described above. The harvested specimens, ap-
proximately 1.5 cm each in length, were thoroughly washed 
two or three times in Hank’s balanced salt solution (HBSS) 
artery bypass grafting (CABG) but also for peripheral vas-
cular surgery.1-3 However, autologous SVGs are often limit-
ed in availability. Various prosthetic small-diameter vascu-
lar conduits have been used alternatively, but the outcomes 
have thus far been disappointing, including those associated 
with arteriovenous fistula (AVF) access creation for hemo-
dialysis, which comprise the bulk of the demand for small-
diameter vascular conduits.4-7
Vascular remodeling-induced premature graft failure is a 
major limitation of small-diameter vascular conduits. Decel-
lularization is potentially an excellent tissue processing meth-
od for increasing the availability of non autologous biologi-
cal small diameter vascular conduits. Removal of antigenic 
determinants may enhance the utility of vascular allograft 
conduits such as cadaveric radial arteries or the saphenous 
vein. However, the propensity for structural deterioration and 
adverse vascular remodeling remain limitations which must 
be resolved through further research. Studies using large ani-
mal models inherently pose difficulties related to higher cost 
and logistical problems. Therefore, the present study was 
conducted to investigate the feasibility of developing a small 
animal surgical model using the rat as a platform for con-
ducting small diameter vascular tissue engineering research. 
MATERIALS AND METHODS
Animal model and surgical procedure
A total of 24 Sprague-Dawley (SD) female rats, 12 donors 
and 12 recipients, each weighing 250 to 300 g, were used. 
Each animal was anesthetized with intra-peritoneal injec-
tion of 0.25 mL of a 2 : 1 : 2 (v/v/v) mixture of Zoletil 50 
(40 mg/kg, Virbac Laboratories, Carros, France), Xylazine 
(10 mg/kg Bayer, Leverkusen, Germany) and 0.9% (w/v) 
physiologic saline. For donor preparation, the abdominal 
aorta was approached via a midline laparotomy incision, af-
ter which the aorta side branches were ligated using poly-
propylene #8-0 monofilament sutures. The aorta was thus 
mobilized from a point just distal to the left renal artery take-
off to the iliac bifurcation. To prevent clotting, heparin (10 
IU/100 g body weight) was injected into the inferior vena 
cava (IVC). The aorta was then resected just distally to the 
renal artery and proximally to the iliac bifurcation. The har-
vested conduit was then flushed with normal saline and 
transferred for decellularization. 
For recipient preparation, anesthesia and aortic mobiliza-
tion were performed in a manner identical to donor prepa-
Fig. 1. Interposition of decellularized aortic conduit in the infrarenal abdom-
inal aorta. Anastomosis was achieved with multiple interrupted Nylon #9-0 
sutures. The proximal part of the graft was marked by P and distal part by D 
in reference to the direction of blood flow.Small-Diameter Decellularized Vascular Allograft
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Willebrand factor was performed using goat anti-PECAM-1 
antibody (1 : 100, catalog no. sc-1506; Santa Cruz Biotech-
nology Inc.) and rabbit anti-von Willebrand factor. Antibody 
reaction was assessed using a rabbit anti-Goat IgG conjugat-
ed Cy3 (catalog no. 305-165-006, Jackson immune research 
laboratories inc., West Grove, Pennsylvania, USA) and goat 
anti-rabbit IgG conjugated alexa 488(catalog no. A-11034, 
Invitrogen inc., Eugene, OR, USA). Samples were subse-
quently counterstained with DAPI (catalog no. D21490, In-
vitrogen Inc., Eugene, OR, USA).
RESULTS
Development and efficacy of animal model 
A pre-study pilot trial was conducted to develop the current 
rat surgical model. High operative and late mortalities were 
encountered during this period due to various forms of tech-
nical failures resulting from inexperience. Surgical bleeding 
accounted for 15 early deaths and suture occlusion of the 
ureter causing a large intra-abdominal renal cyst resulted in 
1 late death. Accidental suturing of the posterior and anterior 
walls accounted for graft failure in another 6 animals. How-
ever, after completion of this developmental phase, a stan-
dardized surgical protocol which resulted in the predictable 
and reliable outcomes of the present study was established. 
Accordingly, the data for the present study were collected 
from animals operated on after this period, and therefore, 
did not include the animals from the pre-study trial. In the 
present series, there were no operative and late deaths, and 
surgery was conducted consecutively in which all animals 
survived the experiment. 
Assessment of decellularization efficacy 
The present decellularization protocol was considered to be 
effective based on the absence of cellular or nucleic compo-
nents in both the luminal surface and the underlying matrix 
scaffolding under high powered light microscopic examina-
tion (400× magnification) of the H&E-stained specimens 
(Fig. 2). The absence of DNA content was also confirmed 
through DAPI staining (Fig. 2C and D) 
Vascular remodeling
Intimal hyperplasia, which appeared as early as 2 weeks 
post-implantation, was characterized by the accumulation of 
collagen and alpha actin-staining smooth muscle cells which 
appeared to be progressive up to 8 weeks. As a result, the in-
and incubated overnight (15-18 hours) at 37ºC in 10 mL of 
physiologic saline containing 0.25% (v/v) Triton X-100 
(Sigma, St. Louis, MO, USA) and 0.25% (w/v) sodium de-
oxycholate in a 10 cm-diameter Petri dish. The aortic seg-
ments were immersed in pre-chilled HBSS and shaken vig-
orously, with solution replacement every 2 hours. To ensure 
detergent elimination, this procedure was repeated three 
times. Each sample was incubated for 15-18  hours at 37ºC 
in 10 mL of PBS containing 150 IU/mL DNase I, 100 µg/
mL RNase A, and 50 mM MgCl2. Samples were again 
shaken in pre-chilled HBSS, with solution replacement ev-
ery 2 hours, as above. Each decellularized aorta was stored 
at 4ºC in physiologic saline until use. Decellularization effi-
cacy was evaluated by high-power light microscopic obser-
vation of hematoxylin and eosin (H&E)-stained specimens.  
Preparation for microscopic study
The implanted grafts were harvested at 2 (n = 6) and 8 (n = 
6) weeks. To avoid endothelial cell sloughing by mechani-
cal trauma, the graft specimens were fixed in 4% (v/v) buff-
ered para-formaldehyde with gentle continuous perfusion at 
60 mmHg prior to extraction. Each of the fixed infrarenal 
aortic specimens was removed en-bloc with a generous at-
tachment of muscle and surrounding tissue. Stretching or 
otherwise traumatic instrumentation of the aorta was avoid-
ed as much as possible. Excess muscle and surrounding tis-
sue were gently trimmed using a surgical microscope. Prior 
to paraffin-embedding, specimens were post-fixed in for-
malin for at least 3 hours. Basic light microscopic staining 
consisted of H&E, Elastica von Gieson (EVG), and Mas-
son Trichrome (MT). 
       
Immunohistochemistry 
Three um thick paraffin-embedded slices were deparaf-
finized and rehydrated in ethanol. The specimens were then 
placed in a solution, containing 0.1% (v/v) Triton X-100 
and 0.05% (v/v) Tween-20 in 0.01 M sodium citrate buffer, 
for antigen retrieval. Immunohistochemistry to detect von 
Willebrand factor and alpha-smooth muscle actin were per-
formed using rabbit anti-human von Willebrand factor anti-
body (1 : 200, catalog no. F3520, Sigma, St. Louis, MO, 
USA) and mouse anti-human smooth muscle actin antibody 
(1 : 100, catalog no. M0851; Dako, Glostrup, Denmark). An-
tibody reaction was assessed using an Envision DAB+ kit 
(catalog no. K4006, K4010, Dako). Samples were subse-
quently counterstained with Mayer’s hematoxylin (catalog 
no. S3309, Dako). Immunohistochemistry for CD31 and von Seong-Jun Hwang, et al.
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the von Willebrand factor staining endothelial like cells to 
stain for CD 31+ as well (Fig. 5).
DISCUSSION
The development of a biologically compatible small-diam-
eter vascular conduit may have far-reaching clinical impli-
cations, especially in situations where autologous conduits 
are either unusable or unavailable. In contrast to the central 
hemodynamic flow conditions of “large-diameter” arterial 
graft conduits, the decreased flow velocity, shear stress, and 
higher vascular resistance of the peripheral vascular system 
contribute to the poorer long term patency of small-diame-
ter vascular conduits.9 Hemodynamic flow conditions have 
been shown to influence vascular remodeling and graft pa-
tency, but properties specifically related to the graft material 
have also been reported to affect graft thrombosis, intimal 
hyperplasia, aneurysm formation, infection, and progres-
sion of atherosclerosis.10 Therefore, improvement of the 
bio-compatibility of vascular scaffolding remains an impor-
tant research objective.
Expanded polytetrafluoroethylene (ePTFE) was widely 
tima at 8 weeks was noticeably thicker with greater intersti-
tial deposition of collagen in the vascular media. Elastic fi-
bers in the normal vascular media appeared to have an 
undulating pattern while those in the decellularized vascular 
implants appeared more straightened with an overall appear-
ance of being more compressed than normal. With regards 
to cellularity, the normal aortic wall media appeared highly 
cellular, whereas the decellularized media appeared sparsely 
cellular with little improvement over time (Fig. 3). 
Immunohistochemical staining 
In the normal aorta, a confluent layer of flattened endothelial 
like cells staining for von Willebrand factor were observed 
on the luminal surface. At 2 weeks after implantation of the 
decellularized vascular implant, however, the surface was 
almost devoid of endothelial like cells. At 8 weeks, the en-
dothelial like cells were more prominent, but showed fewer 
cells than in the normal aortic surface. Similarly, the von 
Willebrand factor staining was more prominent at 8 weeks 
than at 2 weeks, but with noticeably weaker activity than in 
the normal aorta (Fig. 4). To further assess the characteris-
tics of the endothelial like cells, CD 31+ was stained in ad-
dition to that for von Willebrand factor. The results showed 
Fig. 2. Histologic assessment of the decellularized scaffold. (A) Normal aortic wall with a confluent endothelial cell lining and abundant 
cellularity in the native vascular wall matrix. (B) Decellularized vascular scaffold with absence of endothelial cell lining and cellularity or 
nuclear staining within vascular matrix. (C) DAPI staining against DNA content in the aorta with dense cellularity. (D) Post decellularized 




DSmall-Diameter Decellularized Vascular Allograft
Yonsei Med J   http://www.eymj.org   Volume 52   Number 2   March 2011 231
come these limitations included coating with heparin or 
recombinant human thrombomodulin. Nevertheless, the 
outcomes with these methods have not yet been substantiat-
ed through long term studies.12,13
used as an artificial substitute for autologous saphenous 
vein grafts, however, the results have generally been disap-
pointing due to the tendency for accelerated neointimal hy-
perplasia and premature graft failure.3-5,11 Efforts to over-
Fig. 3. Von Gieson’s stain (black, far left column) shows absence of elastin fibers within the intimal proliferative layer. Collagen accumu-
lation (middle column) and actin-positive smooth muscle cells (far right column) are present at 2 weeks. Both the thickness of collage-
nous matrix layer and cells staining positively for actin are increased at 8 weeks. Insert image shows staining without primary antibody.  




Fig. 4. Luminal surfaces of normal and decellularized aortic implant at 2 and 8 weeks. Greater numbers of endothelial cells are seen at 8 
weeks, compared to 2 weeks, but in fewer concentrations than the normal aorta (upper row). Factor VIII staining shows a similar pattern 
correlating with the degree of endothelialization (lower row). Insert shows image of staining without primary antibody.  
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conditions. The relatively larger size and the anticipated 
greater ease of handling for surgery further support the use-
fulness of the present model. The ability to accommodate a 
longer conduit than would be possible in the mouse, the 
amenability to procedural standardization, the ability to 
generate consistent, predictable, and reproducible operative 
outcomes, and the simplification of the anesthesia protocol 
which obviates ventilator requirements, all endorse the rat 
as being the more favorable small animal model. The dem-
onstration of the ability of human mesenchymal stem cells 
(MSCs) to differentiate, survive, and function in a xenoge-
neic non-immune compromised rat environment21 suggest 
further possibilities for using human-origin mesenchymal 
stem cells in a rat vascular implant environment.
For immunohistochemical assessment, several antibodies 
including anti-human antibodies were (anti-vWF and anti-
SMA) used. These anti-human antibodies, which have gen-
erally been adopted in many other animal studies,22,23 led us 
to follow their experimental protocols. In addition, accord-
ing to the manufacturer’s protocols, the antibodies have 
been verified to cross-react against several mammalian spe-
cies such as mouse, rat and chicken, and therefore, have 
been recommended for use with animal tissues.  
From a technical standpoint, the rat aorta, despite its small 
size, does not represent the hemodynamic environment of 
the peripheral vascular system. However, as a platform for 
conducting further research to enhance the utility of decel-
lularized small diameter vascular conduits, the present 
model was suitable for this purpose. Thinning and dilata-
tion with eventual development of aneurysmal changes are 
prominent degenerative findings of small diameter vascular 
conduits. Therefore, we speculated the more densely packed 
Conceptually, decellularization may minimize the inci-
dence of graft failures and complications related to immune 
rejection.14 This contention is supported by the decreased 
mononuclear cell infiltrates observed in decellularized vein 
allograft implants at 2 weeks,15 contrasting with the maxi-
mal inflammatory reaction occurring in fresh venous al-
lografts harvested at similar time points.16 The suitability of 
decellularized vein allograft implants as scaffolding for vas-
cular tissue engineering was suggested earlier by Martin et 
al., showing repopulation of the medial matrix by recipient 
cells at 8 weeks post implantation with excellent retention 
of strength and structural integrity.15 Accordingly, decellu-
larization was considered to be a potentially good method 
for increasing the availability and utility of allograft vein 
grafts, however, it has thus far shown dismal results sec-
ondary to graft rejection and propensity for degenerative 
destruction.17-19 Considering the importance of a functional 
endothelial-cell layer in preventing thrombosis and adverse 
vascular remodeling, further efforts to enhance re-endothe-
lialization and repopulation of the decellularized matrix ap-
pear warranted. 
Foremost is the need to develop a surgical model condu-
cive to efficient and effective data generation and compe-
tence assessment. An animal model using a severely im-
mune-compromised mouse model was previously described 
for such a purpose.20 However, the possibility of graft throm-
bosis and other unforeseen factors that may have been oth-
erwise independently affected by the influence of innate 
platelet dysfunction present in the immune-compromised 
mouse could not be ruled out. Accordingly, the present mod-
el using rats with no such deficiencies may be viewed as 









Fig. 5. DAPI study at 8 weeks showed evenly distributed cellular nuclei in the media of the normal aorta (A and E). In the De-cell specimen it 
was evident mostly in the neo intima layer with sparse cellularity in the media layer. Both the normal and De-cell specimen shows positive 
staining for von WIllebrandt factor (B and F) and CD 31
+ (C and G). These signals were clearly co-localized on the innermost confluent cell 
layer in both groups albeit more strongly present in the normal aorta compared with the decellularized graft. Merging of the von Willebrand 
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Holy Grail? FASEB J 1998;12:43-5.
11. Quiñones-Baldrich WJ, Prego AA, Ucelay-Gomez R, Freischlag 
JA, Ahn SS, Baker JD, et al. Long-term results of infrainguinal re-
vascularization with polytetrafluoroethylene: a ten-year experi-
ence. J Vasc Surg 1992;16:209-17.
12. Ritter EF, Fata MM, Rudner AM, Klitzman B. Heparin bonding 
increases patency of long microvascular prostheses. Plast Reconstr 
Surg 1998;101:142-6.
13. Wong G, Li JM, Hendricks G, Eslami MH, Rohrer MJ, Cutler BS. 
Inhibition of experimental neointimal hyperplasia by recombinant 
human thrombomodulin coated ePTFE stent grafts. J Vasc Surg 
2008;47:608-15.
14. Schaner PJ, Martin ND, Tulenko TN, Shapiro IM, Tarola NA, 
Leichter RF, et al. Decellularized vein as a potential scaffold for 
vascular tissue engineering. J Vasc Surg 2004;40:146-53.
15. Martin ND, Schaner PJ, Tulenko TN, Shapiro IM, Dimatteo CA, 
Williams TK, et al. In vivo behavior of decellularized vein al-
lograft. J Surg Res 2005;129:17-23.
16. Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Fresh venous 
allografts in peripheral arterial reconstruction in dogs. Effects of 
histocompatibility and of short-term immunosuppression with cy-
closporine A and mycophenolate mofetil. J Thorac Cardiovasc 
Surg 1995;110:1732-44.
17. Allaire E, Guettier C, Bruneval P, Plissonnier D, Michel JB. Cell-
free arterial grafts: morphologic characteristics of aortic isografts, 
allografts, and xenografts in rats. J Vasc Surg 1994;19:446-56.
18. Allaire E, Bruneval P, Mandet C, Becquemin JP, Michel JB. The 
immunogenicity of the extracellular matrix in arterial xenografts. 
Surgery 1997;122:73-81.
19. Iaffaldano RA, Lewis BE, Johnson SA, Piffare R, McKiernan TL. 
Patency of cryopreserved saphenous vein grafts as conduits for 
coronary artery bypass surgery. Chest 1995;108:725-9.
20. Lopez-Soler RI, Brennan MP, Goyal A, Wang Y, Fong P, Tellides 
G, et al. Development of a mouse model for evaluation of small 
diameter vascular grafts. J Surg Res 2007;139:1-6.
21. Atoui R, Asenjo JF, Duong M, Chen G, Chiu RC, Shum-Tim D. 
Marrow stromal cells as universal donor cells for myocardial re-
generative therapy: their unique immune tolerance. Ann Thorac 
Surg 2008;85:571-9.
22. Traktuev DO, Tsokolaeva ZI, Shevelev AA, Talitskiy KA, Stepa-
nova VV, Johnstone BH, et al. Urokinase gene transfer augments 
angiogenesis in ischemic skeletal and myocardial muscle. Mol 
Ther 2007;15:1939-46.
23. Pascual G, Martínez S, Rodríguez M, Serrano N, Bellón JM, Buján 
J. Patency and structural changes in cryopreserved arterial grafts 
used as vessel substitutes in the rat. J Surg Res 2005;124:297-304.
24. Lesauskaite V, Tanganelli P, Sassi C, Neri E, Diciolla F, Ivanovi-
ene L, et al. Smooth muscle cells of the media in the dilatative pa-
thology of ascending thoracic aorta: morphology, immunoreactiv-
ity for osteopontin, matrix metalloproteinases, and their inhibitors. 
Hum Pathol 2001;32:1003-11.
25. Ikonomidis JS, Gibson WC, Gardner J, Sweterlitsch S, Thompson 
RP, Mukherjee R, et al. A murine model of thoracic aortic aneu-
rysms. J Surg Res 2003;115:157-63.
appearance of the elastic fibers in the aortic implants to in-
dicate early degenerative changes which may suggest chang-
es representing aneurysmal progression. Although findings 
which are commonly present in established aneurysmal 
transformation such as disruption and fragmentation of the 
elastin fibers were not observed, further long term studies 
are nevertheless warranted to resolve the arguments related 
to this issue.24,25
In conclusion, the present rat small animal model was 
found to be an effective and efficient animal model for con-
ducting vascular tissue engineering research, aimed at en-
hancing the availability and utility of decellularized allograft 
small diameter vascular conduits. 
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